Subtitle
Bone Marrow Sparing by Intensity Modulated Proton Beam Therapy in Postoperative Irradiation of Gynecologic Malignancies.
Subtitle
Bone Marrow Sparing by Intensity Modulated Proton Beam Therapy in Postoperative Irradiation of Gynecologic Malignancies.
Proto therapy Time
May 2024
Executive summary
This matched-pair cohort study from the Heidelberg group evaluated IMPT for 25 patients with uterine cervical (n = 8) or endometrial cancer (n = 17), comparing to IMRT (n=25) in sparing of the pelvic bone marrow and thus reduction of hematotoxicity. In the IMPT group, integral dose to the pelvic skeleton was significantly lower (23.4GyRBE vs 34.3Gy; p < 0.001). Hematotoxicity was significantly more common in the IMRT group (80% vs 32%; p = 0009), especially hematotoxicity ≥ CTCAE II (36% vs 8%; p = 0.037). No patient in the IMPT group experienced hematotoxicity > CTCAE II. In the IMPT cohort, 32% of patients experienced sacral insufficiency fracture (SIF), which appeared similar to reported rates for IMRT in the literature.
Top cancer treatments
Related contents
Proton Therapy Publication
May 2023
Outcomes of Patients Treated in the UK Proton Overseas Programme: Non-central Nervous System Group.
Proton Therapy Publication
November 2022
Outcomes of Proton Beam Therapy Compared With Intensity-Modulated Radiation Therapy for Uterine Cancer.
Proton Therapy Publication
January 2023
Health-related quality of life and patient-reported symptoms after postoperative proton beam radiotherapy of cervical and endometrial cancer: 2-year results of the prospective phase II APROVE-trial.
Proton Therapy Publication
July and August 2023
Treatment Tolerability and Toxicity of Postoperative Proton Beam Therapy for Gynecologic Malignancies: Results of the Prospective Phase 2 APROVE Trial.
Proton Therapy Publication
May 2023
Acute and long-term toxicity of whole pelvis proton radiation therapy for definitive or adjuvant management of gynecologic cancers.